Abstract
Automated lead optimization helper application (ALOHA) is a novel fitness scoring approach for small molecule lead optimization. ALOHA employs a series of generalized Bayesian models trained from public and proprietary pharmacokinetic, absorption, distribution, metabolism, and excretion, and toxicology data to determine regions of chemical space that are likely to have excellent drug-like properties. The input to ALOHA is a list of molecules, and the output is a set of individual probabilities as well as an overall probability that each of the molecules will pass a panel of user selected assays. In addition to providing a summary of how and when to apply ALOHA, this paper will discuss the validation of ALOHA’s Bayesian models and probability fusion approach. Most notably, ALOHA is demonstrated to discriminate between members of the same chemical series with strong statistical significance, suggesting that ALOHA can be used effectively to select compound candidates for synthesis and progression at the lead optimization stage of drug discovery.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Keserü GM, Makara GM (2009) The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 8:203–212
Van de Waterbeemd H, Gifford E (2003) ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2:192–204
Ekins S, Boulanger B, Swaan PW, Hupcey MA (2002) Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J Comput Aided Mol Des 16:381–401
Wager TT, Hou X, Verhoest PR, Villalobos A (2010) Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci 1:435–449
Segall MD (2012) Multi-parameter optimization: identifying high quality compounds with a balance of properties. Curr Pharm Des 18:1292–1310
Ekins S, Boulanger B, Swaan PW, Hupcey MA (2002) Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J Comput Aided Mol Des 16:381–401
Lipinski CA (2009) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235–249
Hughes JD, Blagg J, Price DA, Bailey S, DeCrescenzo GA, Devraj RV, Ellsworth E, Fobian YM, Gibbs ME, Gilles RW, Greene N, Huang E, Krieger-Burke T, Loesel J, Wager T, Whiteley L, Zhang Y (2008) Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 18:4872–4875
Johnson TW, Dress KR, Edwards M (2009) Using the Golden Triangle to optimize clearance and oral absorption. Bioorg Med Chem Lett 19:5560–5564
Marchant CA, Briggs KA, Long A (2008) In silico tools for sharing data and knowledge on toxicity and metabolism: Derek for windows, meteor, and vitic. Toxicol Mech Methods 18:177–187
Fraczkiewicz R, Zhuang D, Zhang J, Miller D, Woltosz WS, Bolger MB (2009) Busting the black box myth: designing out unwanted ADMET properties with machine learning approaches. CICSJ Bull 27:96–102
Wagner TT, Hou X, Verhoest PR, Villalobos A (2010) Moving beyond rules: the development of a central nervous system multiparamter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci 1:435–449
Bickerton GR, Paolini GV, Besnard J, Muresan S, Hopkins AL (2012) Quantifying the chemical beauty of drugs. Nat Chem 4:90–98
Hofer TS (2013) From molecules to electrons—grand challenges in theoretical and computational chemistry. Front Chem 1:1–4
Muchmore SW, Debe DA, Metz JT, Brown SP, Martin YC, Hajduk PJ (2008) Application of belief theory to similarity data fusion for use in analog searching and lead hopping. J Chem Inf Model 48:941–948
Chadwick A, Segall M (2010) Overcoming psychological barriers to good discovery decisions. Drug Discov Today 15:561–569
Stouch TR (2012) The errors of our ways: taking account of error in computer-aided drug design to build confidence intervals for our next 25 years. J Comput Aided Mol Des 26:125–134
Klon AE, Lowrie JF, Diller DJ (2006) Improved naïve bayesian modeling of numerical data for absorpotion, distribution, metabolism and excreation (ADME) property prediction. J Chem Inf Model 46:1945–1956
Nicholls A (2008) What do we know and when do we know it? J Comput Aided Mol Des 22:239–255
Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD (2010) Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem 53:1098–1108
Obach RS, Lombardo F, Waters NJ (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36:1385–1405
Olah M, Mracec M, Ostopovici L, Rad R, Bora A, Hadaruga N, Olah I, Banda M, Simon Z, Mracec M, Oprea TI (2004) In: Oprea TI (ed) Chemoinformatics in drug discovery, Wiley-VCH, New York
Stewart KD, Shiroda M, James CA (2006) Drug Guru: a computer software program for drug design using medicinal chemistry rules. Bioorg Med Chem 14:7011–7022
Acknowledgments
The financial support for this work was provided by AbbVie
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors of this manuscript are employees of AbbVie. AbbVie participated in the interpretation of data, review, and approval of this article.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Debe, D.A., Mamidipaka, R.B., Gregg, R.J. et al. ALOHA: a novel probability fusion approach for scoring multi-parameter drug-likeness during the lead optimization stage of drug discovery. J Comput Aided Mol Des 27, 771–782 (2013). https://doi.org/10.1007/s10822-013-9679-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10822-013-9679-x